Obstructive Airways DiseaseEndoscopic Lung Volume Reduction: Implementation and Practical ConsiderationsNada, Khaled M. MD; Lombard, Gisele BSN, AE-C; Nishi, Shawn P.E. MDAuthor Information Department of Internal Medicine, Division of Pulmonary Critical Care & Sleep Medicine, The University of Texas Medical Branch, Galveston, TX Disclosure: S.P.E.N. is a PulmonX clinical faculty expert for panel discussions and workshops. The remaining authors declare that they have no conflicts of interest. Address correspondence to: Shawn P.E. Nishi, MD, Department of Internal Medicine, Division of Pulmonary Critical Care & Sleep Medicine, The University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555-0561. E-mail: firstname.lastname@example.org. Clinical Pulmonary Medicine: January 2020 - Volume 27 - Issue 1 - p 21-25 doi: 10.1097/CPM.0000000000000345 Buy SDC Metrics Abstract Guidelines for treatment in severe chronic obstructive pulmonary disease with hyperinflation now include endobronchial lung volume reduction. Since December 2018, 2 valve systems have been Food and Drug Administration (FDA) approved, which has generated widespread interest in this new therapy for chronic obstructive pulmonary disease treatment. Although the technical placement of the endobronchial valves is relatively straightforward, this paper focuses on the multidisciplinary approach to identification, evaluation, and follow-up in addition to procedural techniques for endoscopic lung volume reduction implementation. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.